UNSPSC 51263604: Doxazosin mesilate or mesylate

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C23H25N5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86P6PQK0MU, chemically known as piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-, monomethanesulfonate, but more generally known as doxazosin mesylate, which bears US NIH Compound Identifier 3157.

UNSPSC 51263604 Doxazosin mesilate or mesylate is a Commodity code nominally covering a specific alpha-blocker pharmaceutical, but the recent state and local opportunities posted under it show minimal alignment with that narrow scope. The Seminole County, Florida IFB for naloxone and drug deactivation systems and the Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs both address pharmaceutical procurement and pharmacy benefit management but neither centers on doxazosin mesilate as a product line. State and local governments purchasing under this code appear to be acquiring medications and pharmacy services, though the posted opportunities suggest the code may be capturing broader pharmaceutical and pharmacy management activity rather than doxazosin specifically. Issuing bodies include county health departments and state health and human services agencies.

Recent activity appears geographically dispersed across Florida and Texas. Seminole County posted an IFB on June 30, 2026, with a response deadline of July 26, 2023 (note: date discrepancy in source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida; vendors must submit bids electronically and include all shipping costs, with an initial two-year term and one-year renewal option. The Texas HHS Commission issued an RFI on April 3, 2026, requesting vendor capabilities and market intelligence regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to improve prescription fulfillment efficiency and cost management outside traditional pharmacy benefit managers and group purchasing organization channels. The code shows limited recent activity directly relevant to doxazosin mesilate procurement specifically; business development professionals should verify whether opportunities tagged under this commodity truly require the product or reflect broader pharmaceutical and pharmacy benefit management purchasing.